LAURUSLABS Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
Laurus Labs reported a landmark Q2 FY27 with record revenue of INR 2,206 crores and PAT of INR 441 crores, driven by an exceptional 86% YoY growth in its CDMO business. EBITDA margins expanded to 34.5% on improved operational leverage and a favorable product mix. Management is executing a significant transformation strategy, investing heavily in new capabilities and capacities for complex modalities like peptides and oligonucleotides, which are expected to be key growth drivers in the future. While they do not provide specific revenue guidance, they reiterate confidence in sustaining margins above 60% gross and 30% EBITDA.
Management Tone
- Prepared Remarks: Great — The prepared remarks were highly positive, highlighting record revenue and profits, strong growth in the CDMO business, margin expansion, and strategic capacity additions in new modalities like peptides.
- Q&A Session: Good — The Q&A session was engaged and largely positive. Management provided direct answers on several topics while maintaining confidentiality on others. Analysts showed keen interest in the growth trajectory of the CDMO and peptide businesses.
Revenue Growth Drivers
- Robust demand and execution in the CDMO platform, driven by late-stage programs and commercial API supplies
- Stable pricing and expansion of order book in the ARV and developed markets portfolios
- New product launches and integrated CMO engagements in the affordable medicines segment
Growth vs Margin Focus
The company is pursuing a balanced approach. While it is making significant growth-focused capex investments (~INR 1,500 crores annually) in new capacities and technologies, it is also maintaining a strong focus on profitability, re-iterating its guidance of >60% gross margin and >30% EBITDA margin.
About Laurus Labs Limited
Laurus Labs Limited (LAURUSLABS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.